FIG. 3.

Hepatocyte-specific deletion of TRAF2 suppresses the hepatic gluconeogenic program under HFD conditions. A: HKO and control (TRAF2^flox/flox: n = 13; albumin-Cre: n = 3) male mice were fed an HFD for 17 weeks. Mice were fasted for 16 h and intraperitoneally injected with sodium pyruvate (2 g/kg body wt). Blood glucose was monitored after injection, and AUCs were calculated. AU, arbitrary unit. B: Mice (7–8 weeks) were fed an HFD for 10–12 weeks and subjected to ²H NMR analysis. ²H NMR spectra of a MAG derived from plasma glucose (pooled from three animals per group) were presented. C: HKO and control males were fed an HFD for 18 weeks. Total liver RNAs were extracted and used to measure the mRNA abundance of the indicated genes by qPCR. The expression of these genes was normalized to the expression of 36B4. D: HKO and control males were fed an HFD for 18 weeks and fasted for 20–24 h. G6Pase activity was measured in liver microsomal fractions and normalized to microsomal protein levels. E: HKO and control males were fed an HFD for 18 weeks, and liver weight, glycogen contents, and triacylglycerol (TAG) levels were measured. Data are mean ± SEM. *P < 0.05. Con, control.